In a major development for global health, the World Health Organization (WHO) has announced the prequalification of the first-ever malaria treatment designed specifically for newborns and young infants. This groundbreaking announcement, made just ahead of World Malaria Day on April 25th, offers renewed hope in the fight against a disease that has long claimed young lives and devastated communities. The new treatment is formulated for infants weighing between two and five kilograms, addressing a critical gap in care for one of the most vulnerable patient groups.
According to the WHO, the prequalification designation signifies that the medicine meets rigorous international standards for quality, safety, and efficacy. This will be crucial in expanding access to reliable treatments for malaria in infants, who have historically been treated with formulations intended for older children. Such off-label use increases the risk of dosing errors, potential side effects, and reduced treatment effectiveness. The newly prequalified treatment, artemether-lumefantrine, aims to mitigate these risks by providing a precisely formulated option.
Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, expressed the significance of this advancement, stating that for centuries, malaria has inflicted immense suffering, but the landscape is changing. He highlighted the impact of new vaccines, advanced diagnostic tests, next-generation mosquito nets, and now, specialized medicines for the youngest patients. Dr. Ghebreyesus emphasized that ending malaria in our lifetime is no longer a distant dream but a tangible possibility, contingent on sustained political and financial commitment.
The WHO also announced the prequalification of three new rapid diagnostic tests (RDTs) on April 14th. These tests are designed to tackle emerging diagnostic challenges, particularly strains of the malaria parasite that have evolved to become undetectable by conventional HRP2-based RDTs. This evolution has led to a significant number of missed cases, especially in regions like the Horn of Africa, resulting in delayed treatment and increased mortality. The new RDTs aim to improve diagnostic accuracy and ensure timely intervention.
These developments come as the WHO and its partners launch the 2026 World Malaria Day campaign, themed "Driven to End Malaria: Now We Can. Now We Must." The campaign serves as a call to action to seize the current momentum and secure a malaria-free future. Despite progress, the World Malaria Report 2025 indicated an estimated 282 million cases and 610,000 deaths in 2024, highlighting the continued urgency of global efforts to eradicate the disease.